In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altheos Inc.

www.altheos.com

Latest From Altheos Inc.

Recent Financings of Private Companies (09/11)

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

Altheos Inc.

At its inception, Altheos licensed a series of selective Rho-kinase inhibitors for glaucoma from Asahi Kasei Pharma, and it plans to move the lead candidate into clinical trials in the coming year. Although the start-up is behind several companies that already have ongoing ROCK inhibitor trials, Altheos believes its approach to drug discovery and medicinal chemistry make its therapeutic likely to prove itself the best among the new class of medicines for staving off vision loss from glaucoma.
BioPharmaceutical

Eyeing New Drugs For Glaucoma

Demographic shifts leading to an increasing market, unmet medical need and potential interest from Big Pharma buyers are all compelling reasons for VCs to examine closely the opportunity in glaucoma. Add in the fact that because clinical trials are relatively straightforward and quick, it's possible to keep costs manageable, and one might expect venture capitalists to be rushing to form biotech start-ups in the glaucoma arena, especially since there's been no new mechanism of action in glaucoma in a long time. But the hurdle giving venture investors pause is the wholesale restructuring that will come to the glaucoma market next March, when a key patent for Xalatan expires.
BioPharmaceutical Business Strategies

Start-Up Previews (10/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Altheos Inc.
  • Senior Management
  • Henry H Hsu, MD, CEO
    Barbara Wirostko, MD, CMO
    Andrew Lam, Exec. Dir., Prod. Dev.
  • Contact Info
  • Altheos Inc.
    Phone: (650) 989-8570
    601 Gateway Blvd.
    Ste. 250
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register